FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Panel To Mull Risk Plan for Bayers Trasylol

[ Price : $8.95]

An FDA advisory committee reviews a Bayer-proposed risk management plan for Trasylol intended to reduce hypersensitivity reactions...

FDA Clears PreMD Prevu(x) Reader

[ Price : $8.95]

FDA clears a PreMD Inc. 510(k) for a new color reader for its Prevu(x) Point of Care Skin Sterol Test used to assess risk of heart...

Review Period Set for Cydectin

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for patent extension for American Cyanamids Cydectin.

Aptivus Review Period Determined

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Pharmacia & Upjohns Aptivus for patent extension.

Review Period Set for Fuzeon

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Fuzeon is 2,312 days for patent extension.

FDA Determines Review Period for Avastin

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Genentechs Avastin for patent extension.

Macugen Review Period Set

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Gilead Sciences Macugen for patent extension.

Conflicting Studies Added to Ortho Evra Label

[ Price : $8.95]

FDA says labeling for Ortho Evra has been updated with results from two studies on the risk of blood clots.

Review Period Set for Mycamine

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Astellas Pharmas Mycamine for the purpose of patent exten...

Rx Importation Affecting Homeland Security Bill

[ Price : $8.95]

Republican congressional leaders are trying to put down a rank-and-file move to insert drug import legislation in homeland securit...